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  Effects of estramustine phosphate （Estracyt／， EMP） were studied in 20 patients with 一advanced ’
carcinoma of the prostate7 Ten patients received no treatment before EMP－ther4py（g． tucly 1）， and
the other 10 patients received previous estrogen－therapy （study II）． Some of the latter cases showed
resistance to estrog’en－therapy immediately， and the others suffered relapses after varying periods of
remlsslon．
  In s加dy工， EMP showed 75％improvement of su切ective symptom3（dysuria， urination freCSuency
and pain）， and 880／． of objective signs （residual urine， palpation of the prostate and serum prostatic
acid’ Phosphatase）． ln．study II， it showed 250／o improvement of q． ubjective symptoms and 600／， of
objective signs． Comprehehsive evaluation shoi“fed that the effectiveness of EMP on prostatic ¢ar－
cinoma was 900／， in study 1， and 500／， in study II．
  ・The effectiveness of EMP closely’ related to the duration of the remissiQn elicited by’ preceding
estrogen－therapy． ln cases w．here the remission was less than 2 years， the effectiveness of E）．vf？ was’
90tN・100％． However， if the remission was niere than 2 years， it was only 170／．． From these results，．






























は， estradio1－i7β一phosphateにnitrogen mustard を
carbamateとして結合させたもので， estrogen作用
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Fig． 1． Formulae， chemical names， and abbreviations
   （in brackets） of Estracyt and its two main





















の分類2）によると，Study Iがstage C：1例， D：9


























Table 1． Patients treated with estramustine phosphate
Stage No． of cases stuay 1 Study II
C 4 1 3
D 16 9 7
Tota1 20 10 10
Study 1：Patients without previous treatment













































た．Study Iでは10例のすべて， Study IIでは全く
硬結を．ふれなかった1例を除いた9例に異常な腫瘤を
治療前に触れたが，3カ月後には前者の9例，後者の
’1’ab］e 2． Effects of estramustine phosphate on subjective complaints．




Frequent urination9／15 7／10 2／5
Pain 3／8 2／2 1／6
＊Number of patients improved／Number of patients complained before the
              therapy
IVable 3． Effects of estramustine phosphate on objective findings．


















＊Number of patients improved／Number of patients with abnormal
              findings before the therapy．

















































Table 4． Effect of treatment with estramustine phosphate on prostatic carcinoma．
Effect No． of cases Study 1 StudY II
Excellent 7 7
Good ．4 1 3
Slight 3 1 2
None 6 1 5
Tota1 20 10 10





















”rota1 20 7 4 3 6
竹内・ほか：前立腺癌・Estracyt 73．F
Table 6． Side effects of estramustine phosphate．
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